Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Want to see AU:IBX full AI Analyst Report?
IBX Stock Chart & Stats
AU$0.03
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.03
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume347.18K
Average Volume (3M)16.05M
Market Cap
AU$7.36M
Enterprise ValueAU$3.81M
Total Cash (Recent Filing)AU$1.85M
Total Debt (Recent Filing)AU$2.56M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary MagSense PlatformImagion's MagSense platform is a proprietary nanoparticle-based imaging technology that can create a durable technical moat. As a platform asset it supports multiple diagnostic applications, enables IP protection, and underpins long-term product differentiation versus commodity imaging tools.
Focus On Early Breast Cancer DiagnosticsTargeting early breast cancer detection aligns the business with structural tailwinds: widespread screening programs, clinical emphasis on earlier diagnosis, and persistent demand for improved sensitivity. This market focus supports durable commercial opportunity if clinical validation succeeds.
High Gross Profit Margin Observed In 2024An ~85% gross margin in 2024 suggests the underlying technology and unit economics can be highly profitable once revenues scale. High gross margins create room to cover R&D and commercialization expense and support sustainable operating leverage as sales grow long term.
Bears Say
Revenue Fell To Zero In 2025Revenue collapsing to zero is a structural red flag: it prevents validation of product-market fit and recurring commercial demand, forces reliance on financing, and lengthens the timeline to profitable scaling. Absent sustained revenues, operational viability is uncertain.
Negative Equity And Meaningful DebtNegative shareholder equity combined with multi‑million debt balances weakens solvency and constrains financing flexibility. This capital structure increases refinancing and dilution risk, and restricts the company's ability to invest in commercialization without external capital.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means ongoing external funding is required. Even with improved outflows in 2025, a ~4.0M burn rate signals limited runway absent financing, elevating execution risk for clinical programs and commercial rollout over the medium term.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$7.36M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 108 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 490,590,240 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IBX Sentiment 90%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
142.99%
Trailing 12-Months
Asset Growth
-27.09%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---